JPMorgan analyst Brian Cheng raised the firm’s price target on Revolution Medicines (RVMD) to $122 from $92 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines doses first patient in trial evaluating RMC-5127
- Revolution Medicines price target raised to $150 from $75 at Oppenheimer
- Revolution Medicines: Differentiated RAS(ON) Pipeline Underpins Overweight/Buy Rating and $92 December 2026 Target
- Revolution Medicines falls -17.1%
- Revolution Medicines Advances RMC-5127 KRAS Program, Extending Its Oncology Reach